Results 181 to 190 of about 37,867 (235)
Some of the next articles are maybe not open access.
Thrombosis Research, 1987
Antithrombin III (AT III) microheterogeneity was investigated in 12 cases of congenital AT III deficiency and 2 cases of congenital AT III abnormality by isoelectric focusing (IEF) and immunofixation. In congenital AT III deficiency, IEF and immunofixation revealed AT III as 8 bands which was indistinguishable from normal control in terms of the number
N, Sakuragawa +4 more
openaire +2 more sources
Antithrombin III (AT III) microheterogeneity was investigated in 12 cases of congenital AT III deficiency and 2 cases of congenital AT III abnormality by isoelectric focusing (IEF) and immunofixation. In congenital AT III deficiency, IEF and immunofixation revealed AT III as 8 bands which was indistinguishable from normal control in terms of the number
N, Sakuragawa +4 more
openaire +2 more sources
JAMA: The Journal of the American Medical Association, 1978
To the Editor.— In a recent letter to the editor, Rodger L. Bick, MD, commented on methods of assay of antithrombin III (239:296, 1978), pointing out several drawbacks to the use of synthetic chromogenic substrates in such assays. His comments were prompted by an article in MEDICAL NEWS (238:1005, 1977) in which we reported that these peptides were ...
H L, Messmore, J, Fareed
openaire +2 more sources
To the Editor.— In a recent letter to the editor, Rodger L. Bick, MD, commented on methods of assay of antithrombin III (239:296, 1978), pointing out several drawbacks to the use of synthetic chromogenic substrates in such assays. His comments were prompted by an article in MEDICAL NEWS (238:1005, 1977) in which we reported that these peptides were ...
H L, Messmore, J, Fareed
openaire +2 more sources
British Journal of Haematology, 1984
SummaryAntithrombin III (AT‐III) heparin cofactor activity and its antigen levels have been determined in 106 plasma samples from 42 term and preterm neonates. In contrast to healthy adult controls, a reduced activity/antigen (act/ag) ratio (ranging from 0‐26 to 0‐86) was observed in 90% of the samples and was independent of the state of health of the ...
Peters, M. +5 more
openaire +3 more sources
SummaryAntithrombin III (AT‐III) heparin cofactor activity and its antigen levels have been determined in 106 plasma samples from 42 term and preterm neonates. In contrast to healthy adult controls, a reduced activity/antigen (act/ag) ratio (ranging from 0‐26 to 0‐86) was observed in 90% of the samples and was independent of the state of health of the ...
Peters, M. +5 more
openaire +3 more sources
Thrombosis Research, 1982
Plasma from two different thrombophilic families with functional inherited antithrombin III deficiency, i.e., with low antithrombin III activity but normal immunoreactive antithrombin III concentration, were investigated simultaneously in the same laboratory.
P J, Sørensen +5 more
openaire +2 more sources
Plasma from two different thrombophilic families with functional inherited antithrombin III deficiency, i.e., with low antithrombin III activity but normal immunoreactive antithrombin III concentration, were investigated simultaneously in the same laboratory.
P J, Sørensen +5 more
openaire +2 more sources
Hematology/Oncology Clinics of North America, 1992
The general characteristics of antithrombin III (AT III) concentrates available in the United States are described in this article. The effectiveness of AT III concentrates in the prevention and treatment of thrombotic episodes in patients with hereditary AT III deficiency are summarized, and the use of this product in various conditions with acquired ...
openaire +2 more sources
The general characteristics of antithrombin III (AT III) concentrates available in the United States are described in this article. The effectiveness of AT III concentrates in the prevention and treatment of thrombotic episodes in patients with hereditary AT III deficiency are summarized, and the use of this product in various conditions with acquired ...
openaire +2 more sources
Blood Reviews, 1988
A moderate reduction of plasma antithrombin activity is an uncommon but clinically important cause of severe thromboembolic disease. In recent years the molecule responsible for the major part of this activity (antithrombin III) has been extensively characterised and the mode of inheritance of familial deficiencies worked out.
openaire +2 more sources
A moderate reduction of plasma antithrombin activity is an uncommon but clinically important cause of severe thromboembolic disease. In recent years the molecule responsible for the major part of this activity (antithrombin III) has been extensively characterised and the mode of inheritance of familial deficiencies worked out.
openaire +2 more sources
Scandinavian Journal of Urology and Nephrology, 1979
Antithrombin III (AT-III) was measured immunologically in 20 uremic patients on maintenance hemodialysis and in 10 non-dialysed uremic patients. The dialysed patients had slightly elevated AT-III levels. The non-dialysed patients had significantly elevated AT-III levels.
K A, Jørgensen, E, Stoffersen
openaire +2 more sources
Antithrombin III (AT-III) was measured immunologically in 20 uremic patients on maintenance hemodialysis and in 10 non-dialysed uremic patients. The dialysed patients had slightly elevated AT-III levels. The non-dialysed patients had significantly elevated AT-III levels.
K A, Jørgensen, E, Stoffersen
openaire +2 more sources
A new familial variant of antithrombin III: ‘Antithrombin III Paris’
British Journal of Haematology, 1982Summary. A 59‐year‐old woman presented a recurrent history of thromboembolism. A qualitative defect of antithrombin III (AT III) was suggested by the discrepancy between a normal amount of AT III antigen and a decreased heparin cofactor activity. Six members of the same family showed a similar defect although clinically asymptomatic.
M, Wolf +3 more
openaire +2 more sources
Antithrombin III I. Evaluation of an automated antithrombin III method
Thrombosis Research, 1978Abstract An automated method for the determination of antithrombin III activity (as heparin cofactor activity) is described using the chromogenic substrate Chromozym® TH. A linear relationship is obtained between 10–160% of the AT-III activity of normal plasma and there are good correlations with both antigen level as well as with progressive ...
L H, Kahlé +3 more
openaire +2 more sources
Congenital antithrombin III deficient neonate treated with antithrombin III concentrates
Thrombosis Research, 1993A patient with antithrombin III deficiency developed deep vein thrombosis during her first pregnancy. Her pregnancy and delivery were successfully treated with simultaneous administration of antithrombin III concentrates and low molecular weight heparin. She delivered a 2,412g girl at 39 weeks' gestation. The baby was administered with antithrombin III
A, Shiozaki +4 more
openaire +2 more sources